EP0112364A1 - Novel derivatives of guanine ii - Google Patents

Novel derivatives of guanine ii

Info

Publication number
EP0112364A1
EP0112364A1 EP83902142A EP83902142A EP0112364A1 EP 0112364 A1 EP0112364 A1 EP 0112364A1 EP 83902142 A EP83902142 A EP 83902142A EP 83902142 A EP83902142 A EP 83902142A EP 0112364 A1 EP0112364 A1 EP 0112364A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
defined above
hydrogen
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP83902142A
Other languages
German (de)
English (en)
French (fr)
Inventor
Bertil Frank Harald Eriksson
Kristina Birgitta Gotthammar
Karl Nils-Gunnar Johansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astra Lakemedel AB
Original Assignee
Astra Lakemedel AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Lakemedel AB filed Critical Astra Lakemedel AB
Publication of EP0112364A1 publication Critical patent/EP0112364A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom

Definitions

  • the present invention relates to novel derivatives of guanine, methods for their preparation, novel pharmaceutical compositions and use of said compounds in the treatment of virus infections, such as herpes virus infections, which can cause various diseases in an animal or human host, including both common infections and neoplastic diseases, i.e. cancer.
  • the effects of viruses on bodi ly functions is the end result of changes occurring at the cellular and subcellular levels.
  • the pathogenic changes at the cellular level are different for different combinations of viruses and host cells. While some viruses cause a general destruction (killing) of certain cells, other may transform cells to a neoplastic state.
  • herpes dermatitis including herpes labialis
  • herpes keratitis including herpes labialis
  • herpes genitalis including herpes labialis
  • herpes zoster including herpes encephalitis
  • infectious mononucleosis and cytomegalovirus infections all of which are caused by viruses belonging to the herpes-virus group.
  • Other important viral diseases are influenza A and B which are caused by influenza A and B virus respectively.
  • Another important common viral disease is viral hepatitis and especially hepatitis B virus infections are widely spread. Effective and selective antiviral agents are needed for the treatment of these diseases as well as for other diseases caused by viruses.
  • Several different viruses of both DNA and RNA type have been shown to cause tumors in animals.
  • tumor viruses are involved in human tumors.
  • the most likely human cases known today are leucemias, sarcomas, breast carcinomas, Burkitt lymphomas, nasopharyngeal carcinomas and cervical cancers where RNA tumor viruses and herpes viruses are indicated. This makes the search for selective inhibitors of tumorogenic viruses and their functions an important undertaking in the efforts to treat cancer.
  • X is oxygen or sulphur
  • R 1 is hydrogen, halogen, hydroxy, alkoxy, azide, thio, alkylthio, amino, alkylamino, or dialkylamino
  • R 2 is hydrogen, halogen, alkylthio, acylamino, amino or azide
  • R 3 is hydrogen, straight or branch chain or cyclic alkyl, hydroxyalkyl, benzyloxyalkyl, or phenyl
  • R 4 is hydrogen, hydroxy or alkyl
  • R 5 is hydrogen, hydroxy, amino, alkyl, hydroxyalkyl, benzyloxy, benzoyloxy, benzoyloxymethyl, sulphamoyloxy, phosphate carboxypropionyloxy, straight chain or cyclic acyloxy having from 1 to 8 carbon atoms e.g., acetoxy or substituted carbamoyl group of formula NHCO-Z wherein Z is alkyl, aryl or aral
  • R 6 is hydrogen or alkyl, provided that when X is oxygen and R 2 , R 3 , R 4 and R 6 are hydrogen, R 1 is not amino or methyl amino when R 5 is hydrogen or hydroxy.
  • the present invention rel ates to the novel antiviral compound of the formul a
  • R 1 is hydrogen, hydroxy or mercapto and physiologically acceptable salts or optical isomers thereof.
  • the invention thus provides a compound, and physiologically acceptable salts thereof, which compounds are useful in therapeutic and/or prophylactic treatment of viral diseases and which may be useful in therapeutic and/or prophylaotic treatment of cancer caused by viruses.
  • An effective selective antiviral agent with acceptable side effects should have a selective inhibiting effect on a specific viral function of the virus to be combated. It is,therefore, one object of the present invention to provide a novel method for combating virus infections using an antiviral agent which exerts a selective inhibiting effect on viral functions but which exerts only a negligible inhibiting effect on functions of the host cells.
  • the invention also relates to novel pharmaceutical compositions containing the antiviral agents.
  • the present invention relates broadly to a novel method For combating virus infections in animals and man, and compounds to be used at such treatment, it will be particularly useful in the treatment of herpesvirus infections.
  • herpesviruse ⁇ may be mentioned Herpes simplex type 1 and 2, varicella (Herpes zoster), virus causing infectious mononucleos ⁇ s (i.e. Epstein-Barr virus) and cytomegalovirus.
  • Important diseases caused by herpesviruses are herpes dermatitis (including herpes labialis), herpes genitalis, herpes keratitis, herpes encephalitis and herpes zoster.
  • Another possible area of use for the compounds of the present invention are in the treatment of cancer and tumors, particularly those caused by viruses. This effect may be obtained in different ways, i.e. by inhibiting the transformation of virus-infected cells to a neoplastic state, by inhibiting the spread of viruses from transformed cells to other normal cells and by arresting the growth of virustransformed cells.
  • a further area of use for the compounds of the present invention is in the inhibition of transformed cells due to the presence in these, cells of specific herpesvirus enzymes like thymidine kinase.
  • Possible areas of use for the compounds of the present invention with respect to cancer chemotherapy are treatment of leucemias, lymphomas including Burkitt lymphomas and Hodgkin's disease, sarcomas, breast carcinoma, nasopharyngeal carcinomas and cervical cancers in which viruses are indicated.
  • Other possible areas of use for the compounds of the present invention with respect to cancer chemotherapy are treatment of multiple myeloma and cancer of the lungs (and bronchus), the stomach, the liver, the colon, the bladder, the lips, the bones, the kidneys, the ovary, the prostate, the pancreas, the skin (melanoma), the rectum, the salivary glands, the mouth, the esophagus, the testis, the brain (and cranial meninges), the thyroid gland, the gallbladder (and ducts), the nose, the larynx, connective tissues, the penis, the vulvas, the vagina, the corpus uteri and the tongue.
  • the invention furthermore provides
  • A. A method for the treatment of diseases caused by viruses in animals including man, comprising administering to an animal so infected a therapeutically effective amount of a compound of the formula I or a physiologically acceptable salt thereof.
  • B. A method for inhibiting the multiplication of virus, in particular herpesviruses, in animals including man, by administering to an animal in need of such treatment a compound of the formula I or a physiologically acceptable salt thereof in an amount sufficient for inhibiting said multiplication.
  • a method for inhibiting the growth of virus-transformed cells in animals including man characterized by administering to an animal in need of such treatment a compound of the formula I or a physiologically acceptable salt thereof in an amount sufficient for inhibiting said growth.
  • E A method for the treatment of virus-induced neoplastic diseases in animals including man, by inhibiting the multiplication of tumor viruses, characterized by administering to an animal in need of such treatment a compound of the formula I or a physiologically acceptable salt thereof in an amount sufficient for inhibiting such multiplication.
  • F A method for the treatment of neoplastic diseases in animals including man, characterized by administering to an animal a therapeutically effective amount of a compound of the formula I or a physiologically acceptable salt thereof.
  • the invention also relates to the use of a compound of the formula I or a physiologically acceptable salt thereof, in each of the above given methods A, B, C, D, E and F.
  • R 1 is hydrogen, hydroxy or mercapto including physiologically acceptable salts and optical isomers thereof.
  • the compounds of the invention may be obtained by one of the following methods A-D constituting a further aspect of the invention.
  • X is a group such as chlorine, bromine, iodine or a group OSO 2 R 9 where R 9 is alkyl containing 1-8 carbon atoms, fluorinated alkyl containing 1-8 carbon atoms, such as trifluoromethyl, aryl or arylalkyl such as benzyl.
  • Y is hydrogen or a quarternary ammonium ion such as for example tetrabutyl ammonium.
  • R 2 and R 3 are together double-bonded oxygen, i.e. CR 2 R 3 is carbonyl, or alkoxy groups, forming open or cyclic ketals.
  • R 4 is hydrogen or a hydroxy!
  • R 4 examples include acyl groups such as acetyl or benzoyl, alkoxycarbonyl or aryloxycarbonyl groups, silyl groups such as for example tert.-butyl dimethyl silyl, arylalkyl such as benzyl and triarylmethyl or SO 2 R 9 where R 9 is as defined above.
  • R 5 is R 1 as defined above, or OR 4 or SR 4 where R 4 is defined above.
  • R 4 and R 5 may together form an epoxide when R 1 is OH and R 4 and R 5 may additionally form a cyclic derivative such as for example a carbonate ester, carbonate thioester or the corresponding ortho acid cyclic derivatives or cyclic acetal type compounds.
  • a cyclic derivative such as for example a carbonate ester, carbonate thioester or the corresponding ortho acid cyclic derivatives or cyclic acetal type compounds.
  • R 6 is hydroxyl, chlorine, bromine, iodine, thiol, thioether, SO 2 R 9 where R 9 is as defined above; or an oxygen derivative OR 11 whereR 11 is alkyl, arylalkyl such as benzyl, substituted silyl, phosphoryl diester, phosphinothioyl, or SO 2 R 9 where R 9 is as defined above.
  • R 7 and R 8 are the same or different and are hydrogen or R 10 , whereR 10 is an amine protecting group known to those skilled in the art and described for example in “Protective Groups in Organic Chemistry” (T.W. Greene, Wiley 1981), "Methoden der Organischen
  • R 10 are acyl groups, alkoxycarbonyl or aryloxycarbonyl groups or silyl groups.
  • the condensation is preferably conducted in an organic solvent such as for example dimethylformamide, ethanol, acetonitrile or dichloromethane, at a temperature of between 0°C and 100oC for 1 hour to 3 days in the presence of a base (when Y is H) such as for example potassium carbonate.
  • the compounds are hydrolyzed at 0-100oC for 1-24 hours with acid or base such as for example acetic acid, hydrochloric acid (1-35 %) in water, sodium hydroxide (1-20 %) in water, ammonia (1-25 %), in water or methanol, or hydrogenated with, hydrogen gas in an organic solvent such as for example ethanol or dirnethylformamide over a metal catalyst for 1-24 hours at a pressure of 0.1-5 MPa.
  • acid or base such as for example acetic acid, hydrochloric acid (1-35 %) in water, sodium hydroxide (1-20 %) in water, ammonia (1-25 %), in water or methanol, or hydrogenated with, hydrogen gas in an organic solvent such as for example ethanol or dirnethylformamide over a metal catalyst for 1-24 hours at a pressure of 0.1-5 MPa.
  • R 2 , R 3 , R 4 , R 7 and R 8 are as def i n ed above.
  • R 12 is iodine or OSO 2 R 9 where R 9 is as defined above.
  • substitution reactions are performed in an organic solvent such as dimethylformamide, ethanol, acetonitrile or dichloromethane at a temperature of between 0oC and 100°C for 1-24 hours and the substituting reagent will be water, ammonia or hydrogen sulfide or their respective ions or ion pairs.
  • organic solvent such as dimethylformamide, ethanol, acetonitrile or dichloromethane
  • R 4 , R 7 , and R 8 are not hydrogen then in a following reaction they are removed according to method A.
  • R 2 , R 3 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined above.
  • the reduction may be performed with hydrogen gas or hydrogen generated in situ, with a metal as catalyst or with a hydride reducing agent in an organic solvent.
  • C Pyrimidine ring closure to the guanine base of a substituted imidazole derivative.
  • R 2 , R 3 , and R 5 are as defined above, Z is NH 2 or alkoxy i.e. COZ is an amide or ester group and R 13 is NH 2 or guanidine.
  • the ring closure may be performed by known methods, the principles of which are given for example in "Comprehensive Organic Chemistry” p. 505-508 (1979, Vol. 4, D.H.R. Barton and W.D. Ollis eds).
  • the ring closure is performed in an organic solvent at a temperature from 50o to 250°C with or without the addition of a reagent such as for example guanidine.
  • a reagent such as for example guanidine.
  • R 14 is nitroso, nitro, amino, or an amino derivative such as formic amide (-NH-CHO) or amino ortho ester
  • the ring closure may be performed by known methods, the principles of which are given for example in "Comprehensive Organic Chemistry” p. 499-504 (1979, Vol. 4, D.H.R. Barton and W.D. Ollis eds).
  • the ring closure may be performed in an organic solvent such as for example formic acid, formamide, orthoformate ester at a temperature from 50 to 250°C for 1/2 hour to 10 hours.
  • organic solvent such as for example formic acid, formamide, orthoformate ester
  • R 14 is nitroso or nitro
  • these groups first have to be reduced to amino groups by known methods.
  • R 4 is not H and R 5 is not R 1 , then the side chain protecting groups are removed in a following reaction step according to method A.
  • D Substitution in the pyrimidine ring of a purine to the formation of a guanine ring.
  • R 2 , R 3 , R 4 and R 5 are as defined above.
  • Hal is fluoro, chloro, bromo or iodo and R 15 is hydroxyl or amino.
  • the halogen atoms are substituted by ammonia in an organic solvent such as methanol, from normal to higher pressure at room temperature to 100°C for
  • R 15 is amino the amino group can be substituted to a hydroxyl function by selective diazoti zation with nitrite in a solvent such as acetic acid at a temperature from 0oC to 50°C for 1-24 hours, or enzymati cally with adenosinedeaminase in water at a pH from 6 to 9 for 1 to 48 hours.
  • R 4 is not hydrogen and R 5 is not R 1 , then the side chain protecting groups are removed in a following reaction step according to method A.
  • the described methods A-D may be used to give enantiomeric mixtures, or in appropriate cases a single enantiomeric isomer. Additionally a single enantiomeric isomer may be obtained from the enantiomeric mixtures by methods knownper se.
  • the starting materials in the above methods A-D are either known compounds or can be prepared by methods known to those skilled in the art.
  • Physiologically acceptable salts of compounds of the invention are prepared by methods known in the art.
  • the salts are novel compounds and comprise a further aspect of the invention.
  • Metal salts can be prepared by treating a metal hydroxide with a compound of the invention. Examples of metal salts which can be prepared in this way are salts containing Li, Na and K. A less soluble metal salt can be precipitated from a solution of a more soluble salt by addition of a suitable metal compound.
  • Acid salts can be prepared by treating a compound of the invention with an acid as HCl, HBr, H 2 SO 4 , or an organic sulphonic acid.
  • compositions of the compounds of the invention constitute a further aspect of the invention.
  • the compounds of the invention may be administered locally or systemically. They will normally be administered topically, orally, intranasally, by injection or by inhalation in the form of a pharmaceutical composition comprising the active ingredient in the form of the original compound or optionally in the form of a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier which may be a solid, semi-solid or liquid diluent or an ingestible capsule, and such compositions comprise a further aspect of the invention.
  • a pharmaceutically acceptable carrier which may be a solid, semi-solid or liquid diluent or an ingestible capsule, and such compositions comprise a further aspect of the invention.
  • the compound may also be used without carrier material.
  • compositions may be mentioned tablets, drops, such as nasal drops, eye drops, preparations for topical application such as ointments, jellies, creams and suspensions, aerosols for inhalation, nasal spray, liposomes etc.
  • active substance will comprise between 0.01 and 99, or between 0.1 and 99% by weight of the composition, for example between 0.5 and 20% for compositions intended for injection and between 0.1 and 50% for compositions intended for oral administration.
  • the compositions are preferably in dosage unit form. Further, they are preferably provided in sterilized form.
  • the active ingredient may be mixed with a solid, pulverulent carrier, for example lactose, saccharose, sorbitol, mannitol, a starch such as potato starch, corn starch, amylopectin, laminaria powder or citrus pulp powder, a cellulose derivative or gelatine and also may include lubricants such as magnesium or calcium stearate or a Carbowax ® or other polyethylene glycol waxes and compressed to form tablets or cores for dragees. If dragees are required, the cores may be coated for example.
  • a solid, pulverulent carrier for example lactose, saccharose, sorbitol, mannitol, a starch such as potato starch, corn starch, amylopectin, laminaria powder or citrus pulp powder, a cellulose derivative or gelatine and also may include lubricants such as magnesium or calcium stearate or a Carbowax ® or other polyethylene glycol waxes and
  • the active substance may be admixed with a Carbowax ® or a suitable oil as e.g. sesame oil, olive oil, or arachis oil.
  • Hard gelatine capsules may contain granulates of the active substance with solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches (for example potato starch, corn starch or amylopectin), cellulose derivatives or gelatine, and may also include magnesium stearate or stearic acid as lubricants.
  • solid, pulverulent carriers such as lactose, saccharose, sorbitol, mannitol, starches (for example potato starch, corn starch or amylopectin), cellulose derivatives or gelatine, and may also include magnesium stearate or stearic acid as lubricants.
  • sustained release tablets By using several layers of the active drug, separated by slowly dissolving coatings sustained release tablets are obtained. Another way of preparing sustained release tablets is to divide the dose of the active drug into granules with coatings of different thicknesses and compress the granules into tablets together with the carrier substance.
  • the active substance can also be incorporated in slowly dissolving tablets made for instance of fat and wax substances or evenly distributed in a tablet of an insoluble substance such as a physiologically inert plastic substance.
  • Liquid compositions for oral application may be in the form of elixirs, syrups or suspensions, for example solutions containing from about 0.1% to 20% by weight of active substance, sugar and a mixture of ethanol, water, glycerol, propylene glycol and optionally aroma, saccharine and/or carboxymethylcellulose as a dispersing agent.
  • compositions may comprise an aqueous solution of the active drug or a physiologically acceptable salt thereof, desirably in a concentration of 0.05-10%, and optionally also a stabilizing agent and/or buffer substances in aqueous solution. Dosage units of the solution may advantageously be enclosed in ampoules.
  • compositions are suitably in the form of a solution, ointment, gel, suspension, cream or the like.
  • the amount of active substance may vary, for example between 0.05-20% by weight of the active substance.
  • Such compositions for topical application may be prepared in known manner by mixing the active substance with known carrier materials such as isopropanol, glycerol, paraffin, stearyl alcohol, polyethylene glycol, etc.
  • the pharmaceutically acceptable carrier may also include a known chemical absorption promoter. Examples of absorption promoters are e.g. dimethyl-acetamide (US 3,472,931), trichloroethanol or trifl uoroethanol (US 3,891,757), certain alcohols and mixtures thereof (GB 1,001,949).
  • the dosage at which the active ingredients are administered may vary within a wide range and will depend on various factors such as for example the severity of the infection, the age of the patient, etc., and may have to be individually adjusted.
  • As a possible range for the amount of the compounds of the invention which may be administered per day may be mentioned from about 0.1 mg to about 2000 mg or from about 1 mg to about 2000 mg, or preferably from 1 mg to about 2000 mg for topical administration, from 50 mg to about 2000 mg or from 100 to about 1000 mg for oral administration and from 10 mg to about 2000 mg or from 50 to about 500 mg for injection. In severe cases it may be necessary to increase these doses 5-fold to 10-fold. In less severe cases it may be sufficient to use up to 500 or 1000 mg.
  • compositions containing the active ingredients may suitably be formulated so that they provide doses within these ranges either as single dosage units or as multiple dosage units.
  • the compounds of the formula I and the physiologically acceptable salts thereof can be used to inhibit herpesvirus multiplication.
  • the compounds of the formula I and physiologically acceptable salts thereof are useful in therapeutic and/or prophylactic treatment of virus infections.
  • a preferred aspect of the invention is the use of the compounds of the formula I or a physiologically acceptable salt thereof, in the treatment of herpesvirus infections.
  • Butane-1,3-diol (1.0 g) was dissolved in pyridine (50 ml) and cooled to 0°C. Ortho-chlorobenzoyl chloride (1.9 g) was added with stirring.
  • the reaction mixture was kept at 0°C for 1 hour and then at room temperature over night.
  • the solution was poured with stirring into ice-water ( ⁇ 100 ml). After stirring for 15 min the aqueous mixture was extracted with chloroform.
  • the combined chloroform extracts were washed with ice-cold 0.25 M aqueous sulfuric acid, saturated aqueous sodium hydrogen carbonate and water. The dried solution
  • 3-Oxobutyl o-chlorobenzoate (670 mg, 2.96 mmol; prepared according to b)) was dissolved in anhydrous methanol (10 ml). The solution was stirred and cooled in an icebath, and bromine (0.15 ml, 2.96 mmol) was added rapidly. The reaction mixture was kept at +5°C for 18 h. Water (7 ml) and concentrated sulfuric acid (0.6 ml) were added and the mixture was stirred at room temperature over night.
  • active substance denotes a compound according to the present invention or a salt thereof.
  • Each tablet contains:
  • Each suppository contains:
  • Polyethylene glycol 1500 50.0 g
  • Each tablet contains:
  • the inhibiting effect of compounds of the invention on herpesvirus was tested using the method described below.
  • the cellular toxicity of the compounds on host cell functions was also tested.
  • the inhibition of herpesvirus by VIS 590 and VSA 687 has been measured as plaque reduction according to the following procedure.
  • the plaque reduction assay for herpes simplex type 1 was performed on Vero (Green Monkey Kidney) cells as described by Ejercito et al., J. Gen. Virol. 2 (1968) 357. Monolayers on 5 cm petri dishes were used and after virus adsorption the compounds to be tested were added to the medium. The results are shown in table 1.
  • VIS 590 was tested for cellular toxicity as shown in Table 2. The method used has been described by Stenberg (Biochemical Pharmacology, Vol. 30 (1980), 1005-1008). It is seen that VIS 590 did not affect cell growth at 100 ⁇ M. However, at this concentration, herpes virus multiplication was inhibited to more than 90% (see Table 1).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP83902142A 1982-06-21 1983-06-20 Novel derivatives of guanine ii Pending EP0112364A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8203856 1982-06-21
SE8203856A SE8203856D0 (sv) 1982-06-21 1982-06-21 Novel derivatives of guanine ii

Publications (1)

Publication Number Publication Date
EP0112364A1 true EP0112364A1 (en) 1984-07-04

Family

ID=20347138

Family Applications (2)

Application Number Title Priority Date Filing Date
EP83902142A Pending EP0112364A1 (en) 1982-06-21 1983-06-20 Novel derivatives of guanine ii
EP83850171A Expired EP0103552B1 (en) 1982-06-21 1983-06-20 Novel derivatives of guanine

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP83850171A Expired EP0103552B1 (en) 1982-06-21 1983-06-20 Novel derivatives of guanine

Country Status (14)

Country Link
EP (2) EP0112364A1 (enrdf_load_stackoverflow)
JP (1) JPS59501113A (enrdf_load_stackoverflow)
KR (1) KR840005142A (enrdf_load_stackoverflow)
AT (1) ATE19632T1 (enrdf_load_stackoverflow)
DD (1) DD210048A5 (enrdf_load_stackoverflow)
DE (1) DE3363376D1 (enrdf_load_stackoverflow)
ES (1) ES523426A0 (enrdf_load_stackoverflow)
GB (1) GB2122197B (enrdf_load_stackoverflow)
GR (1) GR78622B (enrdf_load_stackoverflow)
NZ (1) NZ204641A (enrdf_load_stackoverflow)
PT (1) PT76903B (enrdf_load_stackoverflow)
SE (1) SE8203856D0 (enrdf_load_stackoverflow)
WO (1) WO1984000168A1 (enrdf_load_stackoverflow)
ZA (1) ZA834531B (enrdf_load_stackoverflow)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5684153A (en) 1984-08-16 1997-11-04 Beecham Group Plc Process for the preparation of purine derivatives
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
US4617304A (en) * 1984-04-10 1986-10-14 Merck & Co., Inc. Purine derivatives
US4916225A (en) * 1986-11-25 1990-04-10 Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr 9-substituted guanines
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
GB201220687D0 (en) * 2012-11-16 2013-01-02 Cross Mfg Co 1938 Ltd Tuft forming apparatus

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4230708A (en) * 1977-10-20 1980-10-28 Stichting Rega V.Z.W. Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
US4221910A (en) * 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
IL64501A (en) * 1980-12-22 1985-07-31 Astra Laekemedel Ab 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8400168A1 *

Also Published As

Publication number Publication date
NZ204641A (en) 1985-10-11
ES8501764A1 (es) 1984-12-01
DE3363376D1 (en) 1986-06-12
ES523426A0 (es) 1984-12-01
KR840005142A (ko) 1984-11-03
GB2122197A (en) 1984-01-11
GR78622B (enrdf_load_stackoverflow) 1984-09-27
JPS59501113A (ja) 1984-06-28
SE8203856D0 (sv) 1982-06-21
ZA834531B (en) 1984-03-28
GB2122197B (en) 1985-10-16
ATE19632T1 (de) 1986-05-15
EP0103552A3 (en) 1984-06-13
EP0103552B1 (en) 1986-05-07
PT76903B (en) 1986-04-09
WO1984000168A1 (en) 1984-01-19
PT76903A (en) 1983-07-01
GB8316742D0 (en) 1983-07-20
EP0103552A2 (en) 1984-03-21
DD210048A5 (de) 1984-05-30

Similar Documents

Publication Publication Date Title
EP0055239B1 (en) Novel derivatives of guanine
EP0165289B1 (en) Novel derivatives of guanine
US5036071A (en) Derivatives of purine
US4294831A (en) Purine derivatives
US4199574A (en) Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4742064A (en) Antiviral carbocyclic analogs of xylofuranosylpurines
US4287188A (en) Purine derivatives
EP0103551B1 (en) Novel derivatives of guanine
EP0103552B1 (en) Novel derivatives of guanine
KR940010033B1 (ko) 항비루스 활성을 갖는 화합물의 제조방법
US4060616A (en) Purine derivatives with repeating unit
KR0159945B1 (ko) 신규 시클로부탄 유도체
US5252575A (en) Antiviral purine derivatives with improved gastrointestinal absorption

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB LI LU NL SE

17P Request for examination filed

Effective date: 19840616

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH DE FR GB LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 83850171.6/0103552 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 18.07.85.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ERIKSSON, BERTIL FRANK HARALD

Inventor name: GOTTHAMMAR, KRISTINA BIRGITTA

Inventor name: JOHANSSON, KARL NILS-GUNNAR